Crossmark

Sustained efficacy following resolution of frequent heartburn with an over-the-counter regimen of esomeprazole 20 mg or placebo for 14 days: two randomized trials

Crossref DOI link: https://doi.org/10.1186/s12876-018-0790-2

Published Online: 2018-05-22

Published Print: 2018-12

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Peura, David A.

Le Moigne, Anne

Wassel, Heather

Pollack, Charles
Funding

Funding for this research was provided by:

Pfizer

AstraZeneca
License Information

Text and Data Mining valid from 2018-05-22
More Information

Article History

Received: 16 November 2017

Accepted: 30 April 2018

First Online: 22 May 2018

Ethics approval and consent to participate

: Informed consent was obtained from all individual participants included in these studies, which were conducted in accordance with the Declaration of Helsinki.The informed consent form and study protocol for each study were approved by Alpha Independent Review Board (San Clemente, California, USA).

: DAP has served as a consultant for AstraZeneca, Pfizer, Takeda, and Horizon.AL is an employee of Pfizer Consumer Healthcare.HW is an employee of Pfizer Consumer Healthcare.CP is a former employee of Pfizer Consumer Healthcare.

: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Document is current

Any future updates will be listed below